Earnings call
Jubilant Ingrevia Q1 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Some of Jubilant Ingrevia's molecules are backed by contracts, including the large CDMO agro molecule; their potential is included in the INR1,500 crore plus figure. The company expects growth in FY 2027 to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls. New plant on Niacinamide is filling up capacity very fast, with volumes already reaching almost 50% plus of what had been envisaged. Revenue grew 25% year-on-year and EBITDA increased 36% year-on-year in Quarter 1 of FY 2027. The company has a leadership position in most of its more than 60 pyridine products and is holding up on pricing in most of them.
The numbers management gave
Results
- Revenue grew 25% year-on-year and EBITDA increased 36% year-on-year in Quarter 1 of FY 2027.
Show source
Revenue grew by 25% year-on- year, while EBITDA increased by 36% year-on-year, reflecting the strength of our business model and disciplined execution across operations.
- Revenue reached a 15-quarter high of INR1,300 crore in Quarter 1 of FY 2027, up 25% year-on-year, driven by healthy volume growth and improved realizations.
Show source
Q1 marked a strong start to the year with revenue reaching a 15-quarter high of INR1,300 crore, up 25% year-on-year, driven by healthy volume growth and improved realizations.
- EBITDA was INR209 crore in Quarter 1 of FY 2027, growing 36% year-on-year and 22% sequentially, while PAT was INR106 crore, up 41% year-on-year and 22% quarter-on-quarter.
Show source
EBITDA increased to INR209 crore, growing 36% year-on-year and 22% sequentially, while PAT stood at INR106 crore, up 41% year-on-year and 22% quarter-on-quarter.
- Specialty Chemicals business reported revenue of INR533 crore in Quarter 1 of FY 2027, up 11% year-on-year and 3% sequentially, supported by steady business volumes and robust growth in Fine Chemicals and CDMO businesses.
Show source
In our Specialty Chemicals business, we delivered revenue of INR533 crore, up 11% year-on-year and 3% sequentially, supported by steady business volumes and robust growth in Fine Chemicals and CDMO businesses.
- Specialty Chemicals business had EBITDA of INR139 crore and margins of 26% in Quarter 1 of FY 2027, benefiting from improved pricing and a richer product mix led by value-added CDMO and fine chemical offerings.
Show source
EBITDA stood at INR139 crore with margins of 26%, benefiting from improved pricing and a richer product mix led by value-added CDMO and fine chemical offerings.
- Nutrition segment reported revenue of INR243 crore in Quarter 1 of FY 2027, up 36% year-on-year and 6% quarter-on-quarter.
Show source
In our Nutrition & Health segment, the Nutrition segment continued its strong momentum with revenue growing to INR243 crore, up 36% year-on- year and 6% quarter-on-quarter.
Show 16 more statements
Results
- Nutrition segment achieved its highest EBITDA in the last 3 years at INR36 crore in Quarter 1 of FY 2027, a 45% year-on-year and 12% sequential increase, while margins improved to 15%.
Show source
We achieved the highest EBITDA in the segment over the last 3 years at INR36 crore, reflecting a 45% year-on- year and 12% sequential increase, while margins improved to 15%.
- Animal Nutrition business had stable Vitamin B3 volumes and substantially improved pricing on both year-on-year and quarter-on-quarter bases in Quarter 1 of FY 2027.
Show source
Vitamin B3 volumes remained stable, while pricing improved substantially on both year-on-year and quarter-on-quarter basis.
- The company maintained its domestic market position in choline and continued to see healthy demand from Europe alongside improved customer realizations in Quarter 1 of FY 2027.
Show source
In choline, we maintained our domestic market position and continued to witness healthy demand from Europe alongside improved customer realizations.
- Chemical Intermediates segment reported revenue of INR524 crore in Quarter 1 of FY 2027, up 38% year-on-year and 21% quarter-on-quarter, driven by strong volume growth and improved realizations, supported by higher input cost pass-throughs.
Show source
Revenue in the segment grew to INR524 crore, up 38% year-on-year and 21% quarter-on-quarter, driven by strong volume growth and improved realizations, supported by higher input cost pass-throughs.
- Chemical Intermediates segment reported EBITDA of INR57 crore in Quarter 1 of FY 2027, up 240% year-on-year and 163% quarter-on-quarter, driven by realization gains across the product portfolio and effective cost pass-through.
Show source
EBITDA for the segment stood at INR57 crore, up 240% year-on-year and 163% quarter-on-quarter, driven by strong realization gains across the product portfolio and effective cost pass- through.
- Growth in Jubilant Ingrevia's specialty business was almost 11% year on year on a like-to-like basis, with a significant portion coming from Fine Chemical and CDMO.
Show source
The more, I think, right way of doing it is to compare it versus last year, where versus last year, we have increased by almost 11% on specialty on a like- to-like basis.
- The company kept pricing in its specialty CDMO and Nutrition segments at Quarter 1 levels.
Show source
And particularly in our specialty CDMO segment and Nutrition segment, we have been able to keep the pricing where they were in Q1.
- Volumes of high-value niacin and niacinamide cosmetic-grade products from the new plant increased in Quarter 1 of FY 2027.
Show source
But the volumes of B3 at the overall segment level have increased.
- Pyridine plant was running at more than 95% utilization in Quarter 1 of FY 2027, with strong volume momentum in pyridine and its derivatives.
Show source
So we are running our plant currently also at 95% plus utilization level.
- Power and fuel expenses increased in Quarter 1 of FY 2027 because year-on-year volumes and the quantity of power and fuel increased, and the Gulf crisis raised LSHS or natural gas costs, increasing the cost of power.
Show source
Second, because of this Gulf crisis, the cost of LSHS or the natural gas has also gone up, which has led to the increase in the cost of power, which is fuel, which is reflected in our P&L. In terms of the other expenses, which you see in the P&L, bulk of the increase is due to the logistic cost where we have been hit by the increase in the cost of logistics, both domestic and international, which is reflected there, which we were able to successfully pass on to our customers as is reflected in our increase in pricing.
- Other expenses increased in Quarter 1 of FY 2027 mainly because domestic and international logistics costs rose; the company passed on the increase to customers, as reflected in its increased pricing.
Show source
Second, because of this Gulf crisis, the cost of LSHS or the natural gas has also gone up, which has led to the increase in the cost of power, which is fuel, which is reflected in our P&L. In terms of the other expenses, which you see in the P&L, bulk of the increase is due to the logistic cost where we have been hit by the increase in the cost of logistics, both domestic and international, which is reflected there, which we were able to successfully pass on to our customers as is reflected in our increase in pricing.
- Specialty Chemicals business had reasonably strong volume growth in Quarter 1 of FY 2027, with CDMO volumes growing versus last quarter, pyridine volumes holding at a steady level, Fine Chemical volumes growing, and a higher-priced product mix and pricing growth also contributing to overall growth.
Show source
So there is a reasonably strong growth on the volume front.
- Quarterly EBITDA was INR209 crore in Quarter 1 of FY 2027, compared with INR100 crore per quarter 3 years back.
Show source
But I think if you see as a portfolio, 3 years back, we were giving INR100 crore EBITDA in a quarter, and now we are at INR209 crore.
- Fine Chemicals and CDMO orders can be pushed out by one quarter or so because of the nature of Jubilant Ingrevia's business.
Show source
Secondly, of course, given the nature of our business, particularly on the Fine Chemicals and CDMO side, there are always some orders which can get pushed off by 1 quarter here and there, which I have explained in the past also, which may be some.
- Pyridine business had stable volume because it is a mature business.
Show source
On rest of the business, the pyridine business is pretty stable in terms of volume because it is a mature business.
- The company carefully built up its high raw-material inventory, and finished-goods prices fell only slightly from their peak.
Show source
Number two, the prices of finished goods, while they came down from the peak a little bit, they did not come down as much.
What it expects ahead
What management expects
- The company expects growth in FY 2027 to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls.
Show source
FY 2027, we expect growth to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls.
- The company is targeting INR100 crore of lean savings in FY27.
Show source
On the operations and ESG front, we remain firmly on track, targeting INR100 crore of lean savings in FY27.
- The company hopes to take Niacinamide plant volumes to 70% of peak volumes very soon in coming quarters.
Show source
And we are hoping in coming quarters, we will be able to take it to 70% of the peak volumes very soon.
- The company would like to keep its full-year EBITDA guidance at INR750 crore to INR800 crore.
Show source
Regarding your first point, whether we want to upgrade our guidance, we would like to stick with the same guidance of INR750 crore to INR800 crore.
- The company expects sequential EBITDA growth, with EBITDA in the first half around INR400 crore plus, in a similar range to the roughly INR200 crore indicated for the first half at a meeting in Bharuch a month earlier.
Show source
It will be in the similar range of what we have indicated when we met in the Bharuch a month back of roughly INR200 crore kind of an EBITDA in the first half will be around INR400 crore plus.
- Specialty and Nutrition have accounted for 70% to 80% of Jubilant Ingrevia's total EBITDA mix; chemical intermediaries are expected to contribute about 15% of total EBITDA, or INR100-odd crore, for the quarter or the year, with the rest from Specialty and Nutrition.
Show source
So if you do the math, 15% of total EBITDA for the quarter or for the year, chemical intermediaries will be coming in the similar range of INR100-odd crore.
Show 14 more statements
What management expects
- Confirmed molecules were expected to contribute at least 25% of its Specialty and Nutrition portfolio together, assuming full revenue from the large contract under the customer agreement; the contribution could be adjusted depending on the large contract's volumes, while EBITDA was expected to remain at the committed level.
Show source
Deepak Jain: See, I think based on our earlier calculations and assuming we get full revenue from the big contract as per the agreement with the customer, the confirmed molecules were supposed to contribute at least 25% of our Specialty and Nutrition portfolio together here.
- The company anticipates sequential improvement in revenue and EBITDA over the coming quarters.
Show source
We anticipate sequential improvement in revenue and EBITDA over the coming quarters.
- The company has certain EBITDA expectations on the contract and maintains that expectation; it is in discussions with the innovator on volume visibility for coming quarters, and the innovator has not finalized its scenarios.
Show source
We maintain that expectation.
- The company expects its fine chemicals, CDMO and nutrition businesses to continue growing in coming quarters; growth in all three high-margin businesses is expected to lift EBITDA in a positive direction.
Show source
So all three businesses are expected to continue to grow in coming quarters.
- For most molecules, customers have provided some visibility on peak volumes two, three or four years ahead, and Jubilant Ingrevia uses assumptions based on that visibility to estimate volumes and revenues.
Show source
Point number two is, in most of those molecules, customers have given us at least some visibility on what their peak volumes would look like in 2 or 3 or 4 years from now.
- The company expects acetyl to continue doing well and is hopeful that customer orders booked will help it beat its target if they materialize in time, supporting sequential improvement; market volatility, particularly in Acetyl, and a possible market downturn in Q3 or Q4 pose a risk.
Show source
And on the back of some of the orders we have booked with the customers, we are hopeful that if they materialize in time, we can hopefully beat the target that we have set for ourselves.
- B3 prices were up in Q1 and had a little spillover effect into Q2; based on historical trends, prices may start to come down by the end of Q2.
Show source
There is a possibility that prices may start to come down by end of Q2 based on historical trends.
- Increasing relative mix of high value-add food grade, pharma grade and cosmetic grade products is expected to limit the impact if B3 pricing comes down.
Show source
The good thing for us is because the relative mix of high value-add products on the food grade, pharma grade and cosmetic grade is increasing, the pricing, even if it comes down, hopefully, it should not impact us significantly.
- The company has already booked a lot of Q2 B3 business, and if pricing comes down, the impact will be on Q3 pricing.
Show source
That will, if at all, pricing comes down, it will have some impact on the Q3 pricing, which we will see.
- Volumes for the large CDMO contract will be higher in the current quarter than in the previous quarter.
Show source
Deepak Jain: Yes, Harsh, the volumes in this quarter will be more than the previous quarter.
- The company has received customer indications of higher volumes for some molecules, and the volumes for at least a few molecules will be higher in their second year than in their first year.
Show source
So there are at least a few molecules where I know the volumes will be higher in second year versus what they were in the first year.
- The company said that individual businesses may not increase every quarter because each business has its own nuances and drivers, and an order moving from one quarter to another can affect its growth trajectory.
Show source
Sometimes one order moving from one quarter to other can reflect differently on the growth trajectory of the business.
- The company said it feels more confident giving guidance on the overall business as a portfolio and is confident it will deliver on the numbers it has committed. Replaced by a later filing.
Show source
And put together, we feel confident that we will deliver on the numbers we have committed.
Orders
- Some of Jubilant Ingrevia's molecules are backed by contracts, including the large CDMO agro molecule; their potential is included in the INR1,500 crore plus figure.
Show source
So obviously, all of that is included in this INR1,500 crore plus of potential.
What it is building and selling
Projects and capacity
- New plant on Niacinamide is filling up capacity very fast, with volumes already reaching almost 50% plus of what had been envisaged.
Show source
The plant is already reaching almost 50% plus volumes versus what we had envisaged.
- Niacin and niacinamide cosmetic-grade products were running at 50% of the plant's 5,000 tons annual capacity, and the company hopes to take utilization to more than 70% by the end of this year.
Show source
As we speak, we are already serving volumes of niacin and niacinamide cosmetic grade, which are the two products for which that plant was created, which are at a 50% of that run rate, and we are hoping to take it up to 70% plus by end of this year.
- New multipurpose plant remains on track for commissioning by the end of the current calendar year, further strengthening its CDMO and Fine Chemicals growth road map.
Show source
In the new multipurpose plant remains on track for commissioning by the end of current calendar year, further strengthening of our CDMO and Fine Chemicals growth road map.
Demand and pricing
- The company has a leadership position in most of its more than 60 pyridine products and is holding up on pricing in most of them.
Show source
In most of them, we have leadership position, and we are holding up on the pricing as well.
- Pricing is holding up in pyridine downstream products, more advanced derivatives and picoline, where the company is increasingly focused.
Show source
But because increasingly, our focus is more on either pyridine downstream, more advanced derivatives or the picoline part of it, where the pricing is holding up.
- Despite continued geopolitical uncertainties in the Middle East, demand across the chemical industry remained resilient and industry volumes stayed stable. Replaced by a later filing.
Show source
Despite continued geopolitical uncertainties in the Middle East, demand across chemical industry has remained resilient.
Show 10 more statements
Segments
- The company added 5 new molecules, most of them from pharma or personal care and at an early stage, and has not updated the INR1,500 crore peak potential number because it is difficult to comment on the new molecules' peak potential; they will provide upside.
Show source
And hence, we have not updated that INR1,500 crore number.
- 10 advanced-stage molecules are not the same molecules as three months earlier: some moved to the confirmed pipeline and others moved into the advanced-stage pipeline.
Show source
So those 10 Page 12 of 20 molecules at advanced stage are not the same molecules which were 3 months back because some of them have moved to confirmed part of the pipeline and some from rest of the pipeline had moved to the advanced stage pipeline.
- The company added 5 new molecules in the last quarter across pharma, semicon and personal care segments.
Show source
We added 5 new molecules in the last quarter across pharma, semicon and Personal Care.
- Overall business mix is roughly 30% pharma, about 20% to 25% agro, 15% to 20% nutrition, about 10% consumer and some industrial.
Show source
And fourth, as I have explained in the past also, if you look at our business mix, we have about 20%, 25% agro, about 30% pharma, about 10% to 15% industrial, 15% nutrition and 10% consumer.
- The company counts molecules as confirmed when customers begin taking commercial volumes, even in small quantities; not all pipeline molecules have multiyear or annual contracts.
Show source
So we start counting them as confirmed molecule as and when customers start taking first commercial volumes from us, even if it is small quantity, that is point number one.
- Molecule pipeline reflects its broader business mix, as the company met customers across all segments when it began the exercise two years ago.
Show source
The broad mix of these molecules as well as broader pipeline also is reflecting that because when we started this exercise 2 years back and we met customers, we met customers across all segments.
- Share of captive consumption across its pyridine and picoline family is increasing and is significant, as B3 volume growth is driving beta-picoline use and the company adds pyridine derivatives and signs new CDMO contracts.
Show source
So in general, our relative share of captive consumption on the whole pyridine and picoline family is increasing, and it is significant.
- Top-of-funnel pipeline is improving. Replaced by a later filing.
Show source
Our funnel at the top part of it is also improving.
Deals and partners
- The company said it has full protection under the large CDMO contract involving revenues of $300 million over 5 years.
Show source
Yes, we have full protection.
- The large CDMO contract customer has not given Jubilant Ingrevia a firm timeline for full volume visibility; the company needs clarity within the next month or so to plan for Q3.
Show source
Unfortunately, they have not given us a firm time line.
Risks, rules and outside factors
Risks and disputes
- The company has full protection under the contract if the innovator gives no volume, which will more than cover the communicated EBITDA expectations.
Show source
But in the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets.
Outside factors
- Despite disruptions in the Middle East affecting global supply chains and price dynamics, Jubilant Ingrevia Limited's diversified sourcing capabilities, customer relationships and operational agility enabled strong business performance and effective cost pass-throughs in Quarter 1 of FY 2027.
Show source
Despite disruptions in the Middle East affecting global supply chains and price dynamics, our diversified sourcing capabilities, customer relationships and operational agility enabled strong business performance and effective cost pass-throughs.
- Finished-goods prices began moving up again in certain segments after the war restarted.
Show source
And number three, which in Page 13 of 20 general is not a good news, but because the war restarted, the finished good prices have started to move up again in certain segments.
- Overcapacity in China is causing more acute pricing pressure for Jubilant Ingrevia's commoditized pyridine variants, including the building block itself.
Show source
The pricing pressure is more acute there because of the overcapacity in China.
Everything else said on the call
What management stressed
- The company has been continuously working on cost improvement for B3 to protect its margins. Replaced by a later filing.
Show source
Secondly, at the same time, we have been continuously working on the cost improvement for that product to ensure we can protect our margins.
Group structure
- The company successfully completed the integration of Remidex Pharma and is witnessing traction from Tier 1 human nutrition customers.
Show source
On the M&A front, we successfully completed the integration of Remidex Pharma, and we are witnessing encouraging traction from Tier 1 human nutrition customers.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Siddharth Gadekar: Good evening. The first question is on the CDMO contract. So can you give us some sense on what was the contribution on the large CDMO contract this quarter? And if the utilization was lower, was the plant reporting an EBITDA loss this quarter?
Answer, deepak jain
Deepak Jain: So Siddharth, I think we shared some light on that at the plant visit also a couple of weeks back, but the plant has been running absolutely smoothly. We started the supplies in March and will continue through Q1 and a Page 6 of 20 significant bump in EBITDA of our Specialty Chemicals business is reflected on the back of those volumes. We did not serve the full volumes last quarter as the innovator had confirmed because in between the raw material prices had escalated due to war and the innovator asked us to take a temporary pause till pricing came down. That was the only challenge by and large, except for some small challenges on the operational front. So, we did make good positive EBITDA on it, which is reflected in the Q1 numbers.
Question
Siddharth Gadekar: And how should we think about the full year EBITDA on this contract if the entire volumes do not come?
Answer, deepak jain
Deepak Jain: So as communicated earlier also, we have certain EBITDA expectations on this contract, which I have announced to the markets in the past and on analyst calls in the past as well. We maintain that expectation. We, of course, are in discussions with the innovator on the volume visibility for coming quarters. They are building their scenarios, as I explained a couple of weeks back as well. They have not finalized and hence, I cannot provide any further visibility. But in the unforeseen circumstances of they not giving us any volume, we have full protection, which will more than cover for whatever EBITDA expectations we have communicated to the markets.
Answer, deepak jain
Deepak Jain: Secondly, we have made a comment on the presentation that we will see sequential growth in the coming quarters. Can you highlight what are the drivers for that growth? And secondly, how should one think about the spreads in 2Q versus 1Q?
Answer, deepak jain
Deepak Jain: If you see our business, and I think this is not different from what we have been communicating in our Pinnacle strategy, the growth drivers in the business are coming from our fine chemicals business, CDMO business and nutrition business. All three businesses are showing sequential growth in terms of volume as well as portfolio expansion as our pipeline also shows. At the same time, the new plant on Niacinamide that we created, we are filling up the capacity very fast. You can see the growth numbers in that business. A lot of it is driven by volume, and we expect to continue on that Page 7 of 20 journey. The plant is already reaching almost 50% plus volumes versus what we had envisaged. And we are hoping in coming quarters, we will be able to take it to 70% of the peak volumes very soon.
Answer, deepak jain
So all three businesses are expected to continue to grow in coming quarters. And all three are high-margin businesses. So that will give a very strong lift in the positive direction to our EBITDA. On top of that, acetyls or chemical intermediates, as you saw in Q1, has done well, and we are seeing that business continue to do well in current quarter as well, especially on the back of the recent escalations in oil price and the raw material prices. So if that continues, then we should be a sequential improvement in EBITDA coming quarters.
Question
Siddharth Gadekar: Just last question on the CDMO funnel. Last quarter, we had indicated we had 20 projects with a potential of around INR1,500 crore peak revenue. That number has increased to 25 projects. Can you give us the peak revenue number for this incremental for the total peak revenue from the CDMO contracts?
Answer, deepak jain
Deepak Jain: Yes. I think so that is a good and valid observation. I think we explained 5 new molecules which we have added. Most of them come from pharma or personal care segment and are early stage. And hence, right now, it is difficult to comment on the peak potential of those new molecules. And hence, we have not updated that INR1,500 crore number. Obviously, there will be upside coming from them.
Answer, deepak jain
And as and when we get visibility from our customers on what kind of peak revenue potential exists in them, we will add to the confirmed revenue potential. But those are good early-stage molecules and will obviously take some time to get further visibility on what their peak potential could look like.
Question
Abhijit Akella: Good evening. Thank you so much and congrats on much improved numbers. First question is just actually a follow-up on the previous one. So Page 8 of 20 this INR1,500 crore order book, would it be possible to just break out by end-use industry, what the rough mix is? That was one. And second, when we talk about pharma or personal care, given that these are early-stage molecules, and as you mentioned, it is difficult to quantify the opportunity there. How exactly have we arrived at the peak order value for these? Is it based on some firm contracts from the customer or how do we think about it? Because it is difficult to quantify just the requirements at early stages.
Answer, deepak jain
Deepak Jain: Okay. Abhijit, This question came, I think, in the last call as well. And I explained that not all molecules in this pipeline are backed up by a multiyear or annual contract. This is based on a very customized set of discussions with the customers where they needed some molecules and we had those chemistries and we created those molecules and started the commercial supplies to them. So we start counting them as confirmed molecule as and when customers start taking first commercial volumes from us, even if it is small quantity, that is point number one. Point number two is, in most of those molecules, customers have given us at least some visibility on what their peak volumes would look like in 2 or 3 or 4 years from now. So we have taken assumptions based on that on what it means for our volumes and our revenues.
Answer, deepak jain
Number three, a couple of these molecules are very big and are backed up with contracts, including the big CDMO agro molecule that we talked about in response to first question. So obviously, all of that is included in this INR1,500 crore plus of potential. And fourth, as I have explained in the past also, if you look at our business mix, we have about 20%, 25% agro, about 30% pharma, about 10% to 15% industrial, 15% nutrition and 10% consumer. The broad mix of these molecules as well as broader pipeline also is reflecting that because when we started this exercise 2 years back and we met customers, we met customers across all segments. Of course the traction is higher in some and lower in some, like agro right now is going through downturn. We do have molecules, of course, the 2 contracts which we have already announced to the market plus a few more. But the speed at which we are moving in agro is relatively slow versus if I compare it with personal care or pharma pipeline because those segments are still holding up in the market, Page 9 of 20 while agro is recovering gradually and will hopefully start to bounce back in the coming quarters.
Question
Abhijit Akella: Yes. Thank you. That is helpful. And the second one I just had was we have done INR209 crore of EBITDA this quarter, and we are talking about sequential growth through the rest of this year. In the context of that, is there any possibility you might want to upgrade your full year guidance of INR750 crore to INR800 crore? Would you see upside to that? And just from the standpoint of the segmental drivers, would it be possible to comment on how much of this increase year-on-year would be driven by spec chems and nutrition versus chemical intermediates?
Answer, varun gupta
Varun Gupta: Abhijit, Varun here. Regarding your first point, whether we want to upgrade our guidance, we would like to stick with the same guidance of INR750 crore to INR800 crore. Sequential growth will be there. It will be in the similar range of what we have indicated when we met in the Bharuch a month back of roughly INR200 crore kind of an EBITDA in the first half will be around INR400 crore plus. And in terms of the mix, bulk of our EBITDA and revenue growth will be done through specialty and nutrition, which has been continuing in the range of 70% to 80% of our EBITDA mix total. So if you do the math, 15% of total EBITDA for the quarter or for the year, chemical intermediaries will be coming in the similar range of INR100-odd crore. The rest all will be through specialty and nutrition.
Answer, deepak jain
Deepak Jain: Yes, Abhijit, I think I will just add one point to what Varun said. The reason we feel hopeful about sequential growth despite the guidance we have given is because we see acetyl doing well and continue to do well in this quarter as well. And on the back of some of the orders we have booked with the customers, we are hopeful that if they materialize in time, we can hopefully beat the target that we have set for ourselves. So that is why there is optimism that we should be able to improve sequentially. But given the volatility which exists in the market, particularly on the Acetyl segment, we never know what happens in Q4. right? So the fundamentals are strong, which make us believe that sequentially will improve. But obviously, there is always a risk if the market go down again in Q3, Q4.
Answer, deepak jain
So that is why we maintain overall guidance at the levels we discussed. Page 10 of 20 Abhijit Akella: Got it.
Question
Great. Just the last one from my side. I will step back in the queue after that. Just in terms of the order book and its materialization into revenues, we are aware of the large agro contract, of course. So that is one. But then what about the rest of the portfolio? How much of a contribution to revenues could that have in this year? And second, from the standpoint of the agro contract itself, should we expect the full annual run rate to be visible this year itself or should we wait for that for another year or so?
Answer, deepak jain
Deepak Jain: See, I think based on our earlier calculations and assuming we get full revenue from the big contract as per the agreement with the customer, the confirmed molecules were supposed to contribute at least 25% of our Specialty and Nutrition portfolio together here. Now obviously, we do not have the visibility on the volumes from big contract, depending on where it lands, at least in revenue terms, there could be some adjustment. But in EBITDA terms, we should still be able to maintain what we have committed, as I explained in response to the first question.
Question
Nitesh Dhoot: Good evening, team. Congratulations on a good set of numbers. My question is on the Specialty Chemical segment numbers that we see. So the sequential increase there is only about INR17 crore in sequential revenue increase, and there is no change in EBITDA if you look at the previous quarter. So taking sequential numbers as our new plant got commercialized towards the end of the last quarter. So would that imply that the segment ex of the agro CDMO contract would have seen some revenue decline? And I mean, any pricing or margin pressures there? Or was the CDMO revenue looking lower than expected there. So could you just clarify?
Answer, deepak jain
Deepak Jain: Yes. So I think the question is valid. And one thing to note is Q4 is always a heavy quarter for us because of the year-end. And what also happens is the customers also slow down their purchase in Q3 because that is year- end for them. They do not want to increase their inventory. So naturally, in Page 11 of 20 Q4, we get benefit from that. So I think from Q4 to Q1, sequential trajectory is not the factor of what is happening in the business.
Answer, deepak jain
Secondly, of course, given the nature of our business, particularly on the Fine Chemicals and CDMO side, there are always some orders which can get pushed off by 1 quarter here and there, which I have explained in the past also, which may be some. So just keep these two factors in mind. But coming back to the specifics of your question, as you rightly said, the business has grown. The CDMO business has also grown, particularly on the back of the big order. And as I explained in response to one of the questions, we have not served the full volume in Q1 because customers asked us to delay some of that to Q2 because of the price escalations on raw material side, which hits them than us because we have to we pass it on to them. So we took some call there. On rest of the business, the pyridine business is pretty stable in terms of volume because it is a mature business.
Answer, deepak jain
There was some pressure on pyridine pricing, which might have offset some part of the growth. The Fine Chemical business also is going strong in terms of both volume as well as holding up on the pricing. But because Q4 is a peak period for Fine Chemicals, again, when you compare Q1 to Q4, you will not see that sequential growth. So it is a combination of factors in our portfolio between CDMO business growing, fine chemicals coming out of a strong base quarter and pyridine stable but some price decline. All those forces put together is essentially what is leading to the kind of INR17 crore growth that we talked about. The more, I think, right way of doing it is to compare it versus last year, where versus last year, we have increased by almost 11% on specialty on a like- to-like basis. And a significant portion of that growth has come from our fine chemical and CDMO.
Answer, deepak jain
Nitesh Dhoot: Sure. So just checking on the confirmed molecule count that has climbed up steadily in the last couple of quarters, 5 every quarter to 25 now. But the advanced stage bucket, that seems to be static at around 10 molecules for 2 straight quarters. So any color that you would want to give there?
Answer, deepak jain
Deepak Jain: Nitesh, you answered the question yourself. The confirmed moving means advance is also moving, right, if it is remaining at 10. So those 10 Page 12 of 20 molecules at advanced stage are not the same molecules which were 3 months back because some of them have moved to confirmed part of the pipeline and some from rest of the pipeline had moved to the advanced stage pipeline. So the whole funnel is moving. Even the 100-plus molecules that we have mentioned even for this quarter is not the same 100 molecules, which we might have explained or announced 2 quarters back because the fact is some of them drop, some new opportunities come. Our funnel at the top part of it is also improving. I just came back from U.S. last week, met 7 customers.
Answer, deepak jain
On the back of that itself, there are at least 10 new opportunities we have now, which is not even reflected in the numbers we announced in the last quarter. So it is a moving funnel. Obviously, at the same time, there are some molecules, customers' plans are changing. So they come back and say that we want to put it on backburner. So it is a very dynamic pipeline. Each number, whether at the top of the funnel of 100-plus molecules or the confirmed molecules or advanced, all 3, the composition is changing every month, I would say, not this quarter.
Question
Nitesh Dhoot: Right. And just one on the nutrition side, if I can squeeze in. So last quarter, I think you had announced that Q1 benefits from the inventory were expected to fade from Q2 onwards. So does that still hold? Have we started seeing any reversal on those benefits? Or we still expect some of these gains to sustain there on the pricing side? And would want to know the capacity utilization at our human grade plant there and what kind of annual EBITDA do you expect from the Nutrition segment overall for FY '27?
Answer, deepak jain
Deepak Jain: Yes. So I think I did mention that remark last call that because the raw material prices were increasing mid-May when we last spoke on this call, so there was this risk of we ending up being with high raw material inventory and pricing of finished good crashing. The good news is, number one, we were very careful in building up the stock of high raw material inventory. So we were very thoughtful and careful. Number two, the prices of finished goods, while they came down from the peak a little bit, they did not come down as much. And particularly in our specialty CDMO segment and Nutrition segment, we have been able to keep the pricing where they were in Q1. And number three, which in Page 13 of 20 general is not a good news, but because the war restarted, the finished good prices have started to move up again in certain segments.
Answer, deepak jain
So because of these three factors, we feel the impact coming from any inventory being carried over from Q1 to Q2 will be very minimal on the business. And hence, to Varun's earlier point, we feel confident about the numbers and the guidance we have given for Q2. To your second part, I think I already answered on the nutrition plant. That plant was created for 5,000 tons annual capacity. As we speak, we are already serving volumes of niacin and niacinamide cosmetic grade, which are the two products for which that plant was created, which are at a 50% of that run rate, and we are hoping to take it up to 70% plus by end of this year.
Question
Archit Joshi: Hi. Good evening. Thanks for the opportunity. A slight clarification. From the presentation, I was reading that B3 volumes, we have mentioned it to be steady. And we have sort of said that the improvement in the quarterly results is coming because of pricing. And at the same time, we have written that strong volumes in niacinamide. So I just wanted to understand what would be the quarterly performance of Human Animal Nutrition business be? And is the pricing sustained in this current environment? And if we can see this INR28-odd crore EBIT number being sustainable for the rest of the financial year? That would be my first one.
Answer, deepak jain
Deepak Jain: So Archit, I think the volumes have increased. They grew steadily. Maybe the English shared is confusing. But the volumes of B3 at the overall segment level have increased. And obviously, the high-value segment that we have started to serve through the niacin and niacinamide cosmetic grade from the new plant, that is also increasing. So I think the English might have confused, but I just explained in response to the previous question, the volumes have increased. Page 14 of 20 The second question is about the pricing of B3.
Answer, deepak jain
Obviously, that is a very volatile territory in the past historically. What we have seen is when prices move up, they stay up for at least 2 to 3 quarters at a time. So prices were up in Q1, and we have a little bit of spillover effect coming into Q2 as well. There is a possibility that prices may start to come down by end of Q2 based on historical trends. The good thing for us is because the relative mix of high value-add products on the food grade, pharma grade and cosmetic grade is increasing, the pricing, even if it comes down, hopefully, it should not impact us significantly. Secondly, at the same time, we have been continuously working on the cost improvement for that product to ensure we can protect our margins. So if we are able to do that, both of those things in the -- depending on where the pricing is towards the end of Q2.
Answer, deepak jain
Q2, we feel comfortable because a lot of booking for Q2, we have already done. That will, if at all, pricing comes down, it will have some impact on the Q3 pricing, which we will see. But as I said, we have already done some mitigation actions, which should hopefully help us in protecting the margins.
Question
Archit Joshi: Got it, sir. Got it. Thanks for answering. The second one on, if you can give some update on the pricing of base pyridines. And how have we fared in the pyridine derivatives? And how do we sort of look at it for the rest of the 9 months growth driver?
Answer, deepak jain
Deepak Jain: Pyridine, as you all know, we are world leaders in pyridine and its derivatives. So we are running our plant currently also at 95% plus utilization level. So we have a strong momentum on the volume side, both on pyridine and its derivatives. The pricing depends on which derivative you are talking about in Pyridine. We do almost 60-plus products. In most of them, we have leadership position, and we are holding up on the pricing as well. There are some commoditized variants of Pyridine, including the building block itself.
Answer, deepak jain
The pricing pressure is more acute there because of the overcapacity in China. But because increasingly, our focus is more on either pyridine downstream, more advanced derivatives or the picoline part of it, where the pricing is holding up. So we are able to manage that business in a fairly steady manner. Page 15 of 20 Archit Joshi: One follow-up on the same one.
Show 9 more questions
Question
To what extent have we internalized the base pyridines for captive use? I am sure the ratio was significantly higher towards base pyridines. I think you had indicated that also in the few con calls in the past. And right now, how much are we captively consuming? And what would be the external sales of base pyridines? That would be my last one. Thank you.
Answer, deepak jain
Deepak Jain: Yes, we never disclosed those numbers specifically, Archit. So I will not be able to give those numbers. But what is more important is that percentage of captive usage is increasing year-on-year, especially a lot of picoline. A lot of beta-picoline particularly goes into B3 requirement. And like I explained in earlier responses to the questions, the B3 volumes are growing substantially for us, which automatically means a lot of beta-picoline is getting used. So the percentage of captive usage is definitely increasing for picoline as well as in our pyridine business, we are doing and adding new derivatives, and we are signing new CDMO contracts pyridine. So in general, our relative share of captive consumption on the whole pyridine and picoline family is increasing, and it is significant.
Question
Harsh Shah: Thank you for the opportunity. You have just mentioned that we will not supply much of the large CDMO contract for this quarter due to the hike in the raw material prices. But can you indicate what about the present quarter? Are the volumes more for this quarter for the particular CDMO contract?
Answer, deepak jain
Deepak Jain: Yes, Harsh, the volumes in this quarter will be more than the previous quarter.
Question
Harsh Shah: My second question is, last year, you have indicated that you have won more than around 15 molecules. And you have said that it takes generally 3 years to reach the peak potential from those molecules. And a few of those molecules will be reaching the second year in this financial year. So can we expect a ramp-up in those molecules? Page 16 of 20 Deepak Jain: Absolutely, there are molecules where we were doing volumes, and we are already getting indication from the customers that they will be giving higher volumes to us.
Answer, deepak jain
Obviously, there is a lead time to all of it. We announced our pipeline first time, I think, last year, probably October. So as we get into the negotiations as well as discussions with the customers, generally, most Western customers give us volume indications by August, September and then confirmation by October for the following year. So there are at least a few molecules where I know the volumes will be higher in second year versus what they were in the first year.
Question
Harsh Shah: My final question would be, despite the massive investment that we have done in renewables and green energies, but our power and fuel expenses have gone sharply for this quarter. And also other expenses have also gone up. Could you explain the nature of these costs? And can we expect the power and fuel expenses to go down from here onwards?
Answer, varun gupta
Varun Gupta: Hi, Harsh. Varun here. So yes, in this quarter, the power and fuel expenses have gone up on account of two reasons. One, first reason is year-on-year, our volumes have increased and so has the quantity of power and fuel. Second, because of this Gulf crisis, the cost of LSHS or the natural gas has also gone up, which has led to the increase in the cost of power, which is fuel, which is reflected in our P&L. In terms of the other expenses, which you see in the P&L, bulk of the increase is due to the logistic cost where we have been hit by the increase in the cost of logistics, both domestic and international, which is reflected there, which we were able to successfully pass on to our customers as is reflected in our increase in pricing.
Question
Harsh Shah: So one last question from my side. Has the large CDMO contract customer, have they given us any time line by which they will be providing us the full volume visibility?
Answer, deepak jain
Deepak Jain: We have been in constant discussions with them. As you know, the market is dynamic. And obviously, they are also listed. I am sure all of you are tracking them as well. As and when they have the visibility, they will provide us. Unfortunately, they have not given us a firm time line. But in order to plan for Q3, we will need some clarity from them within the next month or Page 17 of 20 so.
Answer, deepak jain
So we are hopeful we will get more visibility at least about next quarter by next month.
Question
Rohit Nagraj: Thanks for the opportunity and congrats on a good quarter. First question on the Specialty Chemicals front. We have given in our press release that there has been volume jump as well as pricing increase. So in terms of 11% top line growth on a Y-o-Y basis, what would be the volume and value breakup given that the EBITDA increase is limited to 7%, so there could be some cost inflation transfer? Thank you.
Answer, deepak jain
Deepak Jain: Rohit, we do not give the breakup of volume and price, but it is driven by both. Because as I explained earlier, our CDMO business has grown versus last quarter in terms of volumes. Our pyridine volumes are holding up at least at a steady level. Fine Chemical volumes have also grown. So there is a reasonably strong growth on the volume front. The other thing which is changing in specialty is the mix of the business, which is also giving high-priced products that also adds to the overall growth. And then, of course, there is some contribution coming from pricing growth.
Answer, deepak jain
So it is a mixed bag. It is a healthy growth on volume supported by some price escalation. And obviously, the volume mix, which is being taken in a certain direction.
Question
Rohit Nagraj: Sure. That is helpful. Second question on the Chemical Intermediates front. Now if you look at Y-o-Y basis of the consolidated EBITDA delta of about INR56 crore, almost INR40 crore is contributed from Chemical segment, the Intermediates segment. What gives us confidence that this particular performance will continue in Q2 and thereafter? And an allied question to that, were there any inventory gains during the quarter gone by? Thank you.
Answer, deepak jain
Deepak Jain: Yes, Rohit. So see, that is why we have a portfolio of businesses. Now if you pick one business and say whether we are confident that every quarter, Page 18 of 20 it will start increasing, that becomes slightly sticky because of what I explained earlier that every business has its own nuances and drivers. Sometimes one order moving from one quarter to other can reflect differently on the growth trajectory of the business. But I think if you see as a portfolio, 3 years back, we were giving INR100 crore EBITDA in a quarter, and now we are at INR209 crore. So what is more important is there is a steady growth over the last 3 years. Now in some quarters, some business fires and some business does not fire because of specific factors, which are outside of control.
Answer, deepak jain
But as a portfolio, I think that is why we feel more confident in giving the guidance on the overall business. And you can analyze the last 12 quarter results. There will be quarters when specialty chemicals have fired, there will be quarters when nutrition has fired and there will be quarters when chemical intermediate has fired like the current one. But as a combination, we feel good about the portfolio. And put together, we feel confident that we will deliver on the numbers we have committed.
Question
Rohit Nagraj: Perfect. That is helpful. Just one last clarification. In terms of the large CDMO contract where the revenues of $300 million spanned over 5 years, is there any take-or-pay commitment? And if initially for whatever reasons, if the commitment is lower, can that contract get extended beyond 5 years to fulfill the entire $300 million? Thank you.
Answer, deepak jain
Deepak Jain: No. So, Rohit, we have clarified it multiple times in the past and on this call also, probably even not part of this call earlier. Yes, we have full protection.
Question
Kiran Gadge: Sorry, my question has been answered. Thank you.
Answer, pavleen taneja
We hope we have been able to answer all your queries. For further clarification, I would request you to get in touch with me. Thank you once again for your interest in Jubilant Ingrevia Limited.
Questions about this call
- When was the Jubilant Ingrevia Q1 FY27 earnings call transcript filed?
- Jubilant Ingrevia filed the transcript with the exchange on 27 Jul 2026. This page is built from that transcript.
- What does this page list?
- 64 statements from the transcript across 11 topics, 34 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 19 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.